Advisors Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-5,635
Closed -$207K 647
2026
Q1
$207K Sell
5,635
-2,011
-26% -$95.3K ﹤0.01% 547
2025
Q4
$389K Sell
7,646
-135
-2% -$6.9K ﹤0.01% 454
2025
Q3
$432K Buy
7,781
+174
+2% +$10.2K 0.01% 412
2025
Q2
$525K Sell
7,607
-457
-6% -$31.1K 0.01% 366
2025
Q1
$560K Sell
8,064
-848
-10% -$70K 0.01% 345
2024
Q4
$767K Buy
8,912
+649
+8% +$70.2K 0.01% 326
2024
Q3
$984K Sell
8,263
-3,545
-30% -$473K 0.02% 293
2024
Q2
$1.69M Buy
11,808
+2,355
+25% +$312K 0.03% 258
2024
Q1
$1.21M Buy
9,453
+124
+1% +$14.8K 0.02% 274
2023
Q4
$965K Buy
9,329
+3,335
+56% +$330K 0.02% 292
2023
Q3
$545K Sell
5,994
-1,116
-16% -$98.3K 0.01% 296
2023
Q2
$575K Buy
7,110
+140
+2% +$11.4K 0.01% 298
2023
Q1
$555K Hold
6,970
0.01% 295
2022
Q4
$472K Sell
6,970
-908
-12% -$53.2K 0.01% 317
2022
Q3
$451K Buy
7,878
+3,760
+91% +$201K 0.01% 328
2022
Q2
$229K Sell
4,118
-326
-7% -$18.1K 0.01% 400
2022
Q1
$247K Buy
+4,444
New +$228K 0.01% 392

Other funds holding NVO

Advisors Capital Management's NVO Position: Q2 2026 in Review

Advisors Capital Management sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 5,635 shares — an estimated $207K sold.

Advisors Capital Management first reported a position in NVO in Q1 2022 and held it in 17 quarters. The position peaked at $1.69M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Advisors Capital Management reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Advisors Capital Management sold 5,635 Novo Nordisk shares in Q2 2026, an estimated $207K.
  • Advisors Capital Management first reported a position in Novo Nordisk in Q1 2022 and held it in 17 quarters.
  • Advisors Capital Management's Novo Nordisk position peaked at $1.69M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Advisors Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.